Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.

Abstract

The efficacy, safety, and tolerability of simvastatin (20 mg twice a day) in the treatment of hyperlipidaemia due to unremitting nephrotic syndrome was compared with that of cholestyramine (8 g twice a day) in a crossover trial in ten patients. Two patients were taken off the protocol, one because he could not tolerate cholestyramine and one because of non… (More)

Topics

Cite this paper

@article{Rabelink1988EffectsOS, title={Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.}, author={Antonius J Rabelink and Ronald J. Hen{\'e} and D Willem Erkelens and Jaap A. Joles and Hein A. Koomans}, journal={Lancet}, year={1988}, volume={2 8624}, pages={1335-8} }